OneCell Diagnostics is now 1Cell.Ai
OneCell Diagnostics is now 1Cell.Ai
OncoHRD® is a cutting-edge genomic test specifically designed to detect homologous recombination deficiency (HRD) in solid tumors.
It provides critical insights to guide the use of PARP inhibitors and platinum-based chemotherapy, helping oncologists personalize treatment strategies and improve patient outcomes.
It is commonly associated with breast, ovarian, pancreatic, and prostate cancers, but can be found across a range of solid tumors.
OncoHRD® empowers clinicians by offering a comprehensive, affordable, and AI-powered solution to detect HRD and guide therapy decisions with confidence.
Affordable NGS-based solution with deep sequencing of 50+ HRR pathway genes
Detects SNVs, INDELs, CNVs, structural variants, and HRD-specific genomic scars
Provides HRD scores with LOH, TAI, and LST measurements
Supports selection of targeted therapies including PARP inhibitors
Rapid, AI-powered reporting through the iCARE™ platform
Detection of mutations, deletions, and structural variants across key HRR pathway genes, including BRCA1/2.
Delivers HRD scores based on analysis of Loss of Heterozygosity (LOH), Telomeric Allelic Imbalance (TAI), and Large-Scale State Transitions (LST) — key indicators of homologous recombination deficiency.
HRD-positive status helps identify patients likely to respond to PARP inhibitors and platinum-based chemotherapy.
Comprehensive, easy-to-interpret reports generated through the iCARE™ platform with dynamic AI-supported interpretation.
Identify patients who may benefit from PARP inhibitors or platinum-based therapies
Guide personalized treatment selection in breast, ovarian, prostate, and pancreatic cancers
Enable risk stratification and prognosis prediction based on HRD status
| Sample Type | FFPE tissue block (20–30% tumor content) |
| Sample Collection | 1 FFPE block (preferably <4 months old) |
| cfDNA/DNA Input Amount | >1 ng |
| Sequencing Platform | Illumina NGS (2 × 150 bp paired-end) |
| Sequencing Chemistry | Hybrid capture |
| Analysis Platform | iCARE™ AI-based analysis and dynamic reporting |
More than 50 HRR genes covered in OncoHRD® test
| ARID1A | CDK12 | FANCF | POLE | RPA1 |
| ARID1B | CHEK1 | FANCG | POLH | SMARCA1 |
| ATM | CHEK2 | FANCI | PPP2R1A | TP53 |
| ATR | DNMT1 | FANCL | PPP2R2A | TP53BP1 |
| ATRX | ERCC1 | FANCM | PTEN | WRN |
| AURKA | ERCC4 | HDAC2 | RAD50 | XRCC1 |
| BAP1 | ERCC5 | IRS1 | RAD51 | XRCC2 |
| BARD1 | EXO1 | MLH1 | RAD51B | XRCC3 |
| BLM | FANCA | MRE11 | RAD51C | |
| BRCA1 | FANCC | NBN | RAD51D | |
| BRCA2 | FANCD2 | PALB2 | RAD54B | |
| BRIP1 | FANCE | POLD1 | RAD54L |
BRCA1/2 mutations (germline and somatic)
Non-BRCA HRR genes (including ATM, CHEK2, PALB2, RAD51C, RAD51D, BARD1, FANCA, and more)
Epigenetic Modifications (HRR gene promoter methylation)
Genomic Scars:
Loss of Heterozygosity (LOH)
Telomeric Allelic Imbalance (TAI)
Large-Scale State Transitions (LST)
(Full gene list available upon request.)
Patients with a family history of cancer (breast, ovarian, prostate, pancreatic)
Patients with advanced or metastatic cancers requiring precision therapy
Patients seeking eligibility assessment for PARP inhibitors or platinum-based treatment
Cost-effective deep sequencing of 50+ genes for precision diagnosis
Guides use of PARP inhibitors and platinum chemotherapy
Rapid, AI-generated clinical reports through iCARE™
HRD-positive patients often show better therapy responses
